Thomas Kelly Jr
Concepts (325)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Serine Endopeptidases | 11 | 2016 | 57 | 2.110 |
Why?
| Gelatinases | 11 | 2016 | 36 | 2.090 |
Why?
| Membrane Proteins | 16 | 2023 | 389 | 1.880 |
Why?
| Breast Neoplasms | 14 | 2024 | 1248 | 1.510 |
Why?
| Neoplasm Invasiveness | 9 | 2016 | 295 | 0.950 |
Why?
| Glucuronidase | 5 | 2010 | 48 | 0.910 |
Why?
| Neoplasm Metastasis | 8 | 2011 | 252 | 0.620 |
Why?
| Endopeptidases | 13 | 2016 | 75 | 0.610 |
Why?
| Adenocarcinoma | 3 | 2005 | 428 | 0.570 |
Why?
| Proteoglycans | 5 | 2023 | 96 | 0.500 |
Why?
| Extracellular Matrix | 6 | 2005 | 111 | 0.490 |
Why?
| Syndecan-1 | 4 | 2010 | 82 | 0.490 |
Why?
| Animals | 30 | 2023 | 14385 | 0.470 |
Why?
| Cell Movement | 4 | 2019 | 271 | 0.460 |
Why?
| Cell Line, Tumor | 10 | 2020 | 1550 | 0.440 |
Why?
| Disease | 1 | 2012 | 28 | 0.420 |
Why?
| Cellular Microenvironment | 1 | 2012 | 27 | 0.410 |
Why?
| Cocaine | 2 | 2023 | 184 | 0.400 |
Why?
| Vulvar Neoplasms | 3 | 2016 | 54 | 0.390 |
Why?
| Cell Membrane | 9 | 2005 | 278 | 0.390 |
Why?
| Cell Cycle Proteins | 3 | 2020 | 199 | 0.380 |
Why?
| Fructose | 1 | 2010 | 29 | 0.380 |
Why?
| Antigens, Neoplasm | 2 | 2011 | 170 | 0.380 |
Why?
| Dipeptidyl Peptidase 4 | 3 | 2011 | 13 | 0.380 |
Why?
| Stromal Cells | 3 | 2016 | 79 | 0.370 |
Why?
| Carbon | 1 | 2010 | 61 | 0.370 |
Why?
| Mice | 11 | 2023 | 6413 | 0.370 |
Why?
| Cytoskeletal Proteins | 3 | 2020 | 58 | 0.350 |
Why?
| Dopaminergic Neurons | 3 | 2023 | 23 | 0.340 |
Why?
| Membrane Glycoproteins | 6 | 2005 | 269 | 0.340 |
Why?
| Neovascularization, Pathologic | 3 | 2005 | 168 | 0.340 |
Why?
| Multiple Myeloma | 6 | 2004 | 3035 | 0.330 |
Why?
| Bone and Bones | 2 | 2010 | 516 | 0.330 |
Why?
| Heparan Sulfate Proteoglycans | 2 | 2005 | 14 | 0.320 |
Why?
| Humans | 42 | 2024 | 54284 | 0.320 |
Why?
| Carcinoma, Squamous Cell | 3 | 2016 | 384 | 0.320 |
Why?
| Mammary Neoplasms, Experimental | 2 | 2005 | 135 | 0.310 |
Why?
| Tumor Cells, Cultured | 7 | 2010 | 477 | 0.300 |
Why?
| Osteogenesis | 1 | 2010 | 377 | 0.300 |
Why?
| Cell Adhesion | 7 | 2020 | 171 | 0.300 |
Why?
| Osteoclasts | 1 | 2010 | 469 | 0.290 |
Why?
| Bone Resorption | 2 | 2010 | 326 | 0.290 |
Why?
| RNA, Messenger | 4 | 2023 | 1202 | 0.290 |
Why?
| Female | 21 | 2024 | 28441 | 0.280 |
Why?
| Mice, SCID | 4 | 2010 | 196 | 0.270 |
Why?
| Bone Neoplasms | 2 | 2005 | 193 | 0.270 |
Why?
| Schizosaccharomyces | 1 | 2006 | 53 | 0.270 |
Why?
| Oligosaccharides | 1 | 2005 | 45 | 0.270 |
Why?
| Antibodies, Neoplasm | 1 | 2005 | 35 | 0.270 |
Why?
| Peripheral Nerves | 2 | 2015 | 51 | 0.260 |
Why?
| Education, Medical, Undergraduate | 1 | 2006 | 86 | 0.260 |
Why?
| Medical Oncology | 1 | 2006 | 102 | 0.250 |
Why?
| Nanostructures | 1 | 2005 | 53 | 0.250 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 866 | 0.240 |
Why?
| Extinction, Psychological | 1 | 2023 | 28 | 0.230 |
Why?
| Metalloendopeptidases | 3 | 1998 | 82 | 0.230 |
Why?
| gamma-Aminobutyric Acid | 1 | 2023 | 76 | 0.220 |
Why?
| Fear | 1 | 2023 | 87 | 0.220 |
Why?
| Actins | 5 | 2020 | 132 | 0.220 |
Why?
| Biomedical Research | 1 | 2006 | 240 | 0.220 |
Why?
| Serotonin | 1 | 2023 | 159 | 0.220 |
Why?
| Parkinson Disease, Secondary | 1 | 2021 | 9 | 0.210 |
Why?
| Cell Proliferation | 5 | 2019 | 1096 | 0.210 |
Why?
| Drug-Seeking Behavior | 1 | 2021 | 5 | 0.210 |
Why?
| Phosphodiesterase Inhibitors | 1 | 2021 | 27 | 0.210 |
Why?
| Pyrans | 1 | 2021 | 27 | 0.210 |
Why?
| Reinforcement Schedule | 1 | 2021 | 64 | 0.200 |
Why?
| Cues | 1 | 2021 | 55 | 0.200 |
Why?
| Collagenases | 2 | 1999 | 28 | 0.200 |
Why?
| Receptor, Cannabinoid, CB2 | 1 | 2021 | 60 | 0.200 |
Why?
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2020 | 6 | 0.190 |
Why?
| Neoplasm Proteins | 4 | 1998 | 359 | 0.190 |
Why?
| Radial Artery | 1 | 2020 | 38 | 0.190 |
Why?
| Cyclin-Dependent Kinase 5 | 1 | 2020 | 1 | 0.190 |
Why?
| Pyrimidines | 1 | 2021 | 196 | 0.190 |
Why?
| Pyridines | 1 | 2021 | 137 | 0.190 |
Why?
| Collagen Type I | 2 | 2016 | 97 | 0.190 |
Why?
| Behavior, Animal | 1 | 2021 | 200 | 0.180 |
Why?
| Matrix Metalloproteinases | 1 | 2000 | 52 | 0.180 |
Why?
| Actin Cytoskeleton | 1 | 2020 | 26 | 0.180 |
Why?
| Cyclic AMP | 1 | 2020 | 106 | 0.180 |
Why?
| Neurons | 1 | 2023 | 486 | 0.180 |
Why?
| Immunohistochemistry | 5 | 2016 | 1089 | 0.180 |
Why?
| Lung Neoplasms | 1 | 2005 | 642 | 0.170 |
Why?
| Parkinson Disease | 1 | 2021 | 180 | 0.170 |
Why?
| Neoplasms | 3 | 2009 | 1316 | 0.170 |
Why?
| Pancreas | 1 | 2019 | 80 | 0.170 |
Why?
| Cell Division | 3 | 2004 | 330 | 0.170 |
Why?
| Cocaine-Related Disorders | 1 | 2021 | 246 | 0.170 |
Why?
| Mice, Inbred BALB C | 2 | 2011 | 368 | 0.160 |
Why?
| Cell Transformation, Neoplastic | 1 | 2019 | 200 | 0.160 |
Why?
| Protein Processing, Post-Translational | 1 | 2019 | 183 | 0.160 |
Why?
| Carcinoma, Ductal, Breast | 1 | 1998 | 96 | 0.150 |
Why?
| Phenotype | 3 | 2010 | 820 | 0.150 |
Why?
| Coronary Artery Disease | 1 | 2020 | 329 | 0.140 |
Why?
| Phosphorylation | 3 | 2020 | 614 | 0.140 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2016 | 53 | 0.140 |
Why?
| Scavenger Receptors, Class A | 1 | 2016 | 38 | 0.140 |
Why?
| Cell Transformation, Viral | 3 | 1994 | 27 | 0.130 |
Why?
| Fibroma | 1 | 2015 | 41 | 0.130 |
Why?
| Syndecans | 4 | 2005 | 43 | 0.130 |
Why?
| Avian Sarcoma Viruses | 2 | 1994 | 5 | 0.130 |
Why?
| Neoplasm Transplantation | 2 | 2005 | 94 | 0.130 |
Why?
| Enzyme Activation | 3 | 2006 | 329 | 0.130 |
Why?
| Transplantation, Heterologous | 2 | 2005 | 77 | 0.130 |
Why?
| Extracellular Matrix Proteins | 2 | 1994 | 75 | 0.130 |
Why?
| Fibroblasts | 3 | 1994 | 386 | 0.120 |
Why?
| Transfection | 3 | 2004 | 399 | 0.120 |
Why?
| Neoplasm Recurrence, Local | 2 | 2015 | 644 | 0.120 |
Why?
| Peptide Hydrolases | 2 | 1994 | 67 | 0.120 |
Why?
| Cytoskeleton | 3 | 1989 | 50 | 0.120 |
Why?
| Wnt1 Protein | 1 | 2012 | 12 | 0.110 |
Why?
| Ventral Tegmental Area | 2 | 2023 | 7 | 0.110 |
Why?
| Macrophages | 1 | 2016 | 405 | 0.110 |
Why?
| Phytotherapy | 1 | 2012 | 38 | 0.110 |
Why?
| Mammary Neoplasms, Animal | 1 | 2012 | 38 | 0.110 |
Why?
| Aged, 80 and over | 5 | 2020 | 3431 | 0.110 |
Why?
| Cadherins | 3 | 2016 | 72 | 0.110 |
Why?
| Interleukin-8 | 2 | 2010 | 97 | 0.110 |
Why?
| Chick Embryo | 5 | 1999 | 79 | 0.110 |
Why?
| Serine Proteinase Inhibitors | 1 | 2012 | 10 | 0.110 |
Why?
| Organ Specificity | 1 | 2012 | 126 | 0.100 |
Why?
| Microscopy, Phase-Contrast | 1 | 2010 | 16 | 0.100 |
Why?
| Plant Lectins | 1 | 2010 | 10 | 0.100 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2012 | 173 | 0.100 |
Why?
| PAX2 Transcription Factor | 1 | 2010 | 22 | 0.100 |
Why?
| Signal Transduction | 6 | 2020 | 1753 | 0.090 |
Why?
| Culture Media, Conditioned | 1 | 2010 | 52 | 0.090 |
Why?
| Rats | 3 | 2023 | 3415 | 0.090 |
Why?
| Glycosylation | 1 | 2010 | 112 | 0.090 |
Why?
| Male | 7 | 2023 | 27334 | 0.090 |
Why?
| Carcinoma, Papillary | 1 | 2010 | 65 | 0.090 |
Why?
| Substrate Specificity | 1 | 2010 | 209 | 0.090 |
Why?
| Insulin | 1 | 2012 | 510 | 0.090 |
Why?
| Magnetics | 1 | 2009 | 44 | 0.090 |
Why?
| Acoustics | 1 | 2009 | 38 | 0.090 |
Why?
| Carcinoma, Renal Cell | 1 | 2010 | 120 | 0.090 |
Why?
| Light | 1 | 2009 | 82 | 0.090 |
Why?
| Neoplastic Cells, Circulating | 1 | 2009 | 93 | 0.080 |
Why?
| Kidney Neoplasms | 1 | 2010 | 196 | 0.080 |
Why?
| Neoplasm Staging | 3 | 2016 | 806 | 0.080 |
Why?
| Protein Structure, Tertiary | 3 | 2005 | 289 | 0.080 |
Why?
| Mesoderm | 1 | 2008 | 33 | 0.080 |
Why?
| Diet | 1 | 2012 | 598 | 0.080 |
Why?
| Early Detection of Cancer | 1 | 2009 | 162 | 0.080 |
Why?
| Aged | 7 | 2020 | 10054 | 0.080 |
Why?
| Muscle, Smooth | 1 | 1987 | 68 | 0.080 |
Why?
| Integrins | 3 | 2016 | 36 | 0.080 |
Why?
| Glycoproteins | 1 | 1987 | 132 | 0.080 |
Why?
| Disease Models, Animal | 2 | 2021 | 1639 | 0.070 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 673 | 0.070 |
Why?
| Breast | 2 | 2016 | 92 | 0.070 |
Why?
| DNA, Mitochondrial | 1 | 2008 | 186 | 0.070 |
Why?
| Middle Aged | 7 | 2020 | 13088 | 0.070 |
Why?
| Epithelial Cells | 1 | 2008 | 255 | 0.070 |
Why?
| DNA, Complementary | 2 | 2004 | 145 | 0.070 |
Why?
| Dimerization | 1 | 2006 | 59 | 0.070 |
Why?
| Catalytic Domain | 1 | 2006 | 62 | 0.070 |
Why?
| Blotting, Western | 3 | 2012 | 683 | 0.070 |
Why?
| E-Selectin | 1 | 2005 | 19 | 0.070 |
Why?
| Schizosaccharomyces pombe Proteins | 1 | 2006 | 39 | 0.070 |
Why?
| Lymphatic Metastasis | 2 | 2015 | 256 | 0.070 |
Why?
| Protein Kinases | 1 | 2006 | 89 | 0.070 |
Why?
| Metals | 1 | 2005 | 44 | 0.070 |
Why?
| Pancreatic Neoplasms | 1 | 2008 | 234 | 0.070 |
Why?
| Phototherapy | 1 | 2005 | 53 | 0.070 |
Why?
| Chi-Square Distribution | 2 | 2016 | 318 | 0.070 |
Why?
| Ligands | 1 | 2005 | 230 | 0.070 |
Why?
| Immunoblotting | 2 | 2003 | 134 | 0.060 |
Why?
| Heparitin Sulfate | 1 | 2004 | 10 | 0.060 |
Why?
| Fungal Proteins | 1 | 2006 | 134 | 0.060 |
Why?
| Fibronectins | 2 | 1998 | 41 | 0.060 |
Why?
| Career Choice | 1 | 2006 | 116 | 0.060 |
Why?
| Carcinogens | 2 | 2005 | 231 | 0.060 |
Why?
| Time Factors | 3 | 2015 | 3213 | 0.060 |
Why?
| Matrix Metalloproteinase 9 | 3 | 2002 | 93 | 0.060 |
Why?
| Growth Substances | 2 | 2003 | 32 | 0.060 |
Why?
| Hyperthermia, Induced | 1 | 2005 | 107 | 0.060 |
Why?
| Models, Biological | 2 | 2005 | 823 | 0.060 |
Why?
| Gold | 1 | 2005 | 164 | 0.060 |
Why?
| Osteolysis | 1 | 2004 | 88 | 0.060 |
Why?
| Microfilament Proteins | 2 | 2020 | 47 | 0.060 |
Why?
| Microscopy, Fluorescence | 2 | 2003 | 198 | 0.060 |
Why?
| Receptors, Lipoprotein | 1 | 2003 | 8 | 0.060 |
Why?
| Odds Ratio | 2 | 2015 | 604 | 0.060 |
Why?
| Lipoproteins, HDL | 1 | 2003 | 21 | 0.060 |
Why?
| Antibodies, Monoclonal | 3 | 2023 | 562 | 0.060 |
Why?
| Receptors, Immunologic | 1 | 2003 | 37 | 0.060 |
Why?
| Vimentin | 2 | 2016 | 33 | 0.060 |
Why?
| Chondroitin Sulfate Proteoglycans | 1 | 2023 | 21 | 0.060 |
Why?
| Cells, Cultured | 4 | 2016 | 1737 | 0.060 |
Why?
| Eukaryotic Cells | 1 | 2003 | 20 | 0.060 |
Why?
| Oligonucleotides, Antisense | 1 | 2003 | 29 | 0.060 |
Why?
| Blotting, Northern | 1 | 2003 | 108 | 0.060 |
Why?
| Nitric Oxide Synthase | 1 | 2003 | 102 | 0.060 |
Why?
| Cloning, Molecular | 1 | 2003 | 198 | 0.060 |
Why?
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2023 | 46 | 0.050 |
Why?
| Cell Separation | 1 | 2003 | 107 | 0.050 |
Why?
| Mucous Membrane | 1 | 2002 | 33 | 0.050 |
Why?
| Tumor Microenvironment | 1 | 2024 | 209 | 0.050 |
Why?
| Logistic Models | 2 | 2015 | 995 | 0.050 |
Why?
| Molecular Weight | 3 | 1994 | 100 | 0.050 |
Why?
| Oxidopamine | 1 | 2021 | 4 | 0.050 |
Why?
| Rectum | 1 | 2002 | 51 | 0.050 |
Why?
| Models, Genetic | 1 | 2003 | 209 | 0.050 |
Why?
| Treatment Outcome | 3 | 2020 | 5604 | 0.050 |
Why?
| Rats, Long-Evans | 1 | 2021 | 29 | 0.050 |
Why?
| Estradiol | 1 | 2003 | 219 | 0.050 |
Why?
| Up-Regulation | 1 | 2023 | 508 | 0.050 |
Why?
| Bone Marrow | 1 | 2003 | 411 | 0.050 |
Why?
| Self Administration | 1 | 2021 | 99 | 0.050 |
Why?
| Carcinoma | 1 | 2003 | 153 | 0.050 |
Why?
| Neuronal Plasticity | 1 | 2021 | 58 | 0.050 |
Why?
| Adult | 5 | 2016 | 14207 | 0.050 |
Why?
| Endothelium, Vascular | 1 | 2003 | 288 | 0.050 |
Why?
| Retrospective Studies | 3 | 2020 | 6432 | 0.050 |
Why?
| Biopsy | 2 | 2015 | 692 | 0.050 |
Why?
| Australia | 1 | 2020 | 85 | 0.050 |
Why?
| Neuroprotective Agents | 1 | 2021 | 125 | 0.050 |
Why?
| Gene Expression Regulation | 1 | 2005 | 1062 | 0.050 |
Why?
| Actin Depolymerizing Factors | 1 | 2020 | 5 | 0.050 |
Why?
| Thiazolidines | 1 | 2020 | 6 | 0.050 |
Why?
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2020 | 20 | 0.050 |
Why?
| Propensity Score | 1 | 2020 | 137 | 0.050 |
Why?
| Flow Cytometry | 1 | 2003 | 546 | 0.040 |
Why?
| Recombinant Proteins | 2 | 2016 | 569 | 0.040 |
Why?
| Stress Fibers | 1 | 2019 | 5 | 0.040 |
Why?
| Focal Adhesion Kinase 1 | 1 | 2019 | 15 | 0.040 |
Why?
| Collagen | 2 | 1998 | 223 | 0.040 |
Why?
| HEK293 Cells | 1 | 2020 | 245 | 0.040 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2019 | 55 | 0.040 |
Why?
| Platelet-Derived Growth Factor | 1 | 2019 | 23 | 0.040 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2019 | 55 | 0.040 |
Why?
| HeLa Cells | 1 | 2020 | 291 | 0.040 |
Why?
| Evaluation Studies as Topic | 1 | 1999 | 107 | 0.040 |
Why?
| Pseudopodia | 1 | 1998 | 4 | 0.040 |
Why?
| Bone Remodeling | 1 | 2000 | 177 | 0.040 |
Why?
| RNA, Small Interfering | 1 | 2019 | 252 | 0.040 |
Why?
| Thiophenes | 1 | 1998 | 37 | 0.040 |
Why?
| Gene Expression Profiling | 1 | 2003 | 1138 | 0.040 |
Why?
| Prostatic Neoplasms | 1 | 2002 | 415 | 0.040 |
Why?
| Linear Models | 1 | 1999 | 309 | 0.040 |
Why?
| Survival Rate | 1 | 2020 | 951 | 0.040 |
Why?
| Phenylalanine | 1 | 1998 | 125 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 1 | 2021 | 1476 | 0.040 |
Why?
| Databases, Factual | 1 | 2020 | 684 | 0.040 |
Why?
| Antineoplastic Agents | 1 | 2005 | 1300 | 0.040 |
Why?
| Risk Factors | 2 | 2015 | 3935 | 0.040 |
Why?
| Lymph Nodes | 1 | 1998 | 284 | 0.030 |
Why?
| Antiporters | 1 | 2015 | 19 | 0.030 |
Why?
| beta Catenin | 1 | 2016 | 102 | 0.030 |
Why?
| Enzyme Inhibitors | 1 | 1998 | 446 | 0.030 |
Why?
| Anion Exchange Protein 1, Erythrocyte | 1 | 2015 | 15 | 0.030 |
Why?
| S100 Proteins | 1 | 2015 | 41 | 0.030 |
Why?
| Young Adult | 2 | 2015 | 4318 | 0.030 |
Why?
| Mice, Inbred C57BL | 2 | 2016 | 1999 | 0.030 |
Why?
| Antigens, CD | 1 | 2016 | 242 | 0.030 |
Why?
| Neoplasm, Residual | 1 | 2015 | 166 | 0.030 |
Why?
| Protease Inhibitors | 1 | 1994 | 64 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2015 | 643 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 165 | 0.030 |
Why?
| Lactation | 1 | 2012 | 61 | 0.030 |
Why?
| Disease Progression | 1 | 2015 | 913 | 0.030 |
Why?
| Mutation | 1 | 2019 | 1501 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 206 | 0.030 |
Why?
| Cell Nucleus | 2 | 2010 | 203 | 0.030 |
Why?
| Melanoma | 1 | 1994 | 313 | 0.020 |
Why?
| Mice, Transgenic | 1 | 2012 | 656 | 0.020 |
Why?
| Cross Reactions | 2 | 1987 | 56 | 0.020 |
Why?
| Rheology | 1 | 2009 | 12 | 0.020 |
Why?
| Molecular Mimicry | 1 | 2009 | 64 | 0.020 |
Why?
| Matrix Metalloproteinase 2 | 2 | 2002 | 64 | 0.020 |
Why?
| Receptors, Transforming Growth Factor beta | 1 | 2008 | 26 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2010 | 923 | 0.020 |
Why?
| Microscopy, Electron | 1 | 1987 | 97 | 0.020 |
Why?
| Nanoparticles | 1 | 2009 | 173 | 0.020 |
Why?
| Transforming Growth Factor beta | 1 | 2008 | 158 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2010 | 1048 | 0.020 |
Why?
| Chickens | 1 | 1987 | 118 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1136 | 0.020 |
Why?
| Fibroblast Growth Factor 2 | 1 | 2005 | 33 | 0.020 |
Why?
| Kidney | 1 | 2010 | 820 | 0.020 |
Why?
| Pregnancy | 1 | 2012 | 2620 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2005 | 230 | 0.020 |
Why?
| Scavenger Receptors, Class B | 1 | 2003 | 10 | 0.010 |
Why?
| Receptors, Scavenger | 1 | 2003 | 28 | 0.010 |
Why?
| Hormone Replacement Therapy | 1 | 2003 | 27 | 0.010 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2003 | 83 | 0.010 |
Why?
| Spectrin | 1 | 1982 | 3 | 0.010 |
Why?
| Ovariectomy | 1 | 2003 | 125 | 0.010 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2003 | 84 | 0.010 |
Why?
| Brain Chemistry | 1 | 1982 | 75 | 0.010 |
Why?
| Vasodilation | 1 | 2003 | 106 | 0.010 |
Why?
| Protein Transport | 1 | 2003 | 195 | 0.010 |
Why?
| Femoral Artery | 1 | 2003 | 122 | 0.010 |
Why?
| Endoscopy | 1 | 2002 | 131 | 0.010 |
Why?
| Neutrophils | 1 | 2002 | 154 | 0.010 |
Why?
| Sex Factors | 1 | 2003 | 767 | 0.010 |
Why?
| Mice, Knockout | 1 | 2003 | 926 | 0.010 |
Why?
| beta 2-Microglobulin | 1 | 1997 | 35 | 0.010 |
Why?
| Rhodamines | 1 | 1993 | 3 | 0.010 |
Why?
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 1993 | 12 | 0.010 |
Why?
| Cell Adhesion Molecules | 1 | 1994 | 87 | 0.010 |
Why?
| Gelatin | 1 | 1993 | 26 | 0.010 |
Why?
| Biotin | 1 | 1993 | 45 | 0.010 |
Why?
| Binding Sites | 1 | 1993 | 440 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 1993 | 767 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 1993 | 980 | 0.010 |
Why?
| Talin | 1 | 1989 | 3 | 0.010 |
Why?
| Concanavalin A | 1 | 1989 | 20 | 0.010 |
Why?
| Microspheres | 1 | 1989 | 34 | 0.010 |
Why?
| Cell Line, Transformed | 1 | 1989 | 88 | 0.010 |
Why?
| Protein Binding | 1 | 1989 | 736 | 0.000 |
Why?
| Vinculin | 1 | 1982 | 3 | 0.000 |
Why?
| Actinin | 1 | 1982 | 2 | 0.000 |
Why?
| Immune Sera | 1 | 1982 | 24 | 0.000 |
Why?
| Ankyrins | 1 | 1982 | 10 | 0.000 |
Why?
| Erythrocyte Membrane | 1 | 1982 | 15 | 0.000 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1982 | 124 | 0.000 |
Why?
| Fluorescent Antibody Technique | 1 | 1982 | 141 | 0.000 |
Why?
| Epitopes | 1 | 1982 | 89 | 0.000 |
Why?
| Cattle | 1 | 1982 | 224 | 0.000 |
Why?
| Terminology as Topic | 1 | 1982 | 72 | 0.000 |
Why?
| Swine | 1 | 1982 | 431 | 0.000 |
Why?
| Muscle Proteins | 1 | 1982 | 307 | 0.000 |
Why?
|
|
Kelly Jr's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|